Anti-dual integrin antibodies, compositions, methods and uses

Details Anti-dual integrin antibodies, compositions, methods and uses Anti-dual integrin antibodies, compositions, methods and uses

2007-10-30

2007-10-30

Haddad, Maher M. (Department: 1644)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S445000, C435S326000, C435S252300, C435S320100, C536S023530

Reexamination Certificate

active

09920267

ABSTRACT:
The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

REFERENCES:
patent: 5674483 (1997-10-01), Tu et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 5985278 (1999-11-01), Mitjans et al.
patent: 6171588 (2001-01-01), Carron et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6359126 (2002-03-01), Kim et al.
patent: 6369204 (2002-04-01), Kim et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 2001/0011125 (2001-08-01), Huse
patent: 2003/0143603 (2003-07-01), Giles-Komar et al.
patent: 0 260 829 (1988-03-01), None
patent: 719859 (1996-07-01), None
patent: 0 834 557 (1998-04-01), None
patent: WO93/20229 (1993-10-01), None
patent: WO94/12181 (1994-06-01), None
patent: WO95/25543 (1995-09-01), None
patent: WO97/06791 (1997-02-01), None
patent: WO97/36859 (1997-10-01), None
patent: WO 0031248 (2000-06-01), None
patent: WO 0044404 (2000-08-01), None
Rudikoff et al Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Gunther Gastl, Thomas Hermann, Michael Steurer, Jorg Zmija, Eberhard Gunsilius, Clemens Unger, and Andrea Kraft, “Angiogenesis as a target for tumor treatment”, Oncology, 1997, 177-84, vol. 54.
Brian P. Eliceiri and David A. Cheresh, “The Role of alpha-v integrins during angiogenesis: insights into potential mechanisms of action and clinical development”, The Journal of Clinical Investigation, May 1999, 1227-30, vol. 103, No. 9.
Martin Friedlander, Peter C. Brooks, Robert W. Shaffer, Christine M. Kincaid, Judith A. Varner, and David A. Cherish, “Definition of two angiogenic pathways by distinct alpha-v integrins”, Science, Dec. 1 1995, 1500-2, vol. 270.
Lisa D. Taylor, Condie E. Carmack, Dennis Huszar, Kay M. Higgins, Roshanak Mashayekh, Getachew Sequar, Stephen R. Schramm, Chiung-Chi Kuo, Susan L. O'Donnell, Robert M. Kay, Clive S. Woodhouse, and Nils Lonberg, “Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM”, International Immunology, 1994; 579-91, vol. 6, No. 4, Oxford University Press.
Nils Lonberg, Lisa D. Taylor, Fiona A. Harding, Mary Trounstine, Kay M. Higgins, Stephen R. Schramm, Chiung-Chi Kuo, Roshanak Mashayekh, Kathryn Wymore, James G. McCabe, Donna Munoz-O'Regan, Susan L. O'Donnell, Elizabeth S. G. Lapachet, Tasha Bengoechea, Dianne M. Fishwild, Condie E. Carmack, Robert M. Kay, and Dennis Huszar, “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Nature, Apr. 28, 1994, 856-9, vol. 368.
Michael Neuberger, “Generating high-avidity human Mabs in mice”, Nature Biotechnology, Jul. 1996, 826, vol. 14.
Dianne M. Fishwild, Susan L. O'Donnell, Tasha Bengoechea, Debra V. Hudson, Fiona Harding, Susan L. Bernhard, Debbie Jones, Robert M. Kay, Kay M. Higgins, Stephen R. Schramm, and Nils Lonberg, “High-avidity human IgG-kappa monoclonal antibodies from a novel strain of minitocus transgenic mice”, Nature Biotechnology, Jul. 1996, 845-51, vol. 14.
Elizabeth A. Wayner, Robert A. Orlando, and David A. Cheresh, “Integrins alpha v beta 3 and alpha v beta 5 Contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface”, J. Cell Biology, May 1991, 919-29, vol. 113, No. 4.
John F. Marshall, Deborah C. Rutherford, Alison C.E. McCartney, Francesc Mitjans, Simon L. Goodman, and Ian R. Hart, “Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin”, J. of Cell Science, 1995, 1227-38, vol. 108.
David A. Cheresh and Robert C. Spiro, “Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor”, J. of Biological Chemistry, Dec. 25, 1987, 17703-11, vol. 262, No. 36.
Hans Kemperman, Yvonne M. Wijnands, and Ed Roos, “Alpha v Integrins on HT-29 Colon Carcinoma Cells: Adhesion to Fibronectin is Mediated Solely by Small Amounts of alpha v beta 6, and alpha v beta 5 is Codistributed with Actin Fibers”, Experimental Cell Research, 1997, 156-64, vol. 234.
Maxime Lehmann, Chantal Rabenandrasana, Richard Tamura, Jean-Claude Lissitzky, Vito Quaranta, Jacques Pichon, and Jacques Marvaldi, “A Monoclonal Antibody Inhibits Adhesion to Fibronectin and Vitronectin of a Colon Carcinoma Cell Line and Recongizes the Integrins alpha v beta 3, alpha v beta 5, and alpha v beta 6”, Cancer Research, Apr. 15, 1994, 2102-07, vol. 54.
Tam, S., et al.: “Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent alfinity and functional blockade of glycoprotein IIB/IIIa and alpha (v) beta2 integrins” vol., 98, No. 11, Sep. 15, 1998, pp. 1085-1091, XP000882678.
Trikha, M. et al.: “A potential new application for a cardiovascular drug: Role for ReoPro (Abciximab), an inhibitor of gpllb/llla and alphaVbeta3 integrins, as an anti-cancer agent”, Proceedings of the American Association for Cancer Research, vol. 41, Mar. 2000, p. 577, XP002212901.
Suzuki, S., et al.: “cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors”. Proceedings of the National Academy of Sciences of the U.S.A., vol. 83, No. 22, Nov. 1986, pp. 8614-8618, XP002212902.
Mitjans et al, “In Vivo Therapy of Malignant Melanoma by Means of Antagonists of αv Integrins,” Int. J. Cancer, 2000, pp. 716-723, vol. 87, Wiley-Liss, Inc., Spain.
Mitjans et al, “An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice,” Journal of Cell Science, 1995, pp. 2825-2838, vol. 108, The Company of Biologists Limited, Great Britain.
Casel et al, “RGD Peptides and Moncolonal Antibodies, Antagonists of αv-Integrin, Enter the Cells by Independent Endocytic Pathways,” Laboratory Investigation, 2001, pp. 1615-1626, vol. 81, No. 12, The United States and Canadian Academy of Pathology, Inc., USA.
Panka et. al., Variable Region Framework Differences Result In Decreased Or Increased Affinity Of Variant Anti-Digoxin Antibodies, Proc. Natl. Acad. Sci. U.S.A. 85(9); 3080-3084, 1988.
Amit, et. al., Three-Dimensional Structure Of An Antigen-Antibody Complex At 2.8 Resolution. Science. 233 (4765); 747-753, 1986.
Wayner et. al., Integrins Alpha V Beta 3 And Alpha V Beta 5 Contribute To Cell Attachment To Vitronectin But Differentially Distribute on the Cell Surface. J. Cell Biol. May 1991; 113(4);919-29.
J. Orihara, Sensitizing Capacity, Cross- Reactivity And Antigenic Determinants Of Bisphenal A, The Journal Of Stomatological Society, vol. 59, No. 2, Jun. 1992, pp. 439-455, English Abstract.
M. Castillo et. al., “Analysis Of Industrial Effluents To Determine Endocrine-Disrupting Chemicals”, Trends In Analytical Chemistry vol. 16, No. 10, Nov. 12, 1997, pp. 574-583.
J. Gascon et. al. “Detection Of Endocrine-Disrupting Pesticides By Enzyme-Linked Immunosorbent Assay (Elisa); Application To Atrazine” Trends In Analytical Chemistry, vol. 16, No. 10, 1997, pp. 554-562.
Friendlander et. al, Proc Natl Acad Sci, 1996, pp. 9764-9769, vol. 93.
Chemicon International Catalog No. MAB1953Z, p. 1, Jan. 27, 2006.

Affiliated with

Also associated with

Rating

Anti-dual integrin antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-dual integrin antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-dual integrin antibodies, compositions, methods and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3898971